Primary Care Perspectives on Alzheimer’s Disease: Adaptive Strategies to Improve Cognitive Assessment, Promote Earlier Diagnosis, and Optimize Care
This activity is designed to meet the educational needs of physicians attending AAFP Chapter Meetings across the U.S.
- Review the etiology, epidemiology, and multifaceted pathophysiology of Alzheimer’s disease (AD), highlighting pathologic processes that may manifest years before symptom onset.
- Discuss the paramount importance of symptom recognition and routine screening protocols to identify mild cognitive impairment (MCI) and promote early AD diagnosis.
- Evaluate currently-available cognitive assessment tools, with an emphasis on those best suited for the primary care setting, and summarize expert consensus AD diagnostic criteria across the disease continuum.
- Examine how biomarker-driven disease characterization, including blood-based metrics, supports timely and accurate AD diagnosis and treatment initiation.
- Use real-world cases from the primary care perspective to design evidence-supported and patient-centric diagnostic plans that incorporate shared decision making and multidisciplinary and interprofessional referrals.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Genentech
5 min Welcome and Introductions/Pre-test
10 min Fundamental Facets of Alzheimer’s Disease: Epidemiology, Pathophysiology, and the Critical Need for Early Diagnosis
20 min Recognizing Early Cognitive Decline: Principal Pillars of Cognitive Assessment in the Primary Care Setting
15 min Fortifying the Frontline: The Sentinel Role of the Primary Care Clinician on the Comprehensive Care Team
10 min Conversations with the Experts: Audience Q&A/Post-test
Gregory A. Jicha, MD, PhD
Professor of Neurology
Robert T. & Nyles Y. McCowan Endowed Chair in Alzheimer's Disease
Sanders-Brown Center on Aging
University of Kentucky Alzheimer's Disease Center
University of Kentucky
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Mark J. Huffmyer, PharmD, BCGP, BCACP–has no relevant financial relationships to disclose in relation to the content of this activity.
Alireza Atri, MD, PhD–disclosures to come.
Gregory A. Jicha, MD, PhD–has disclosed that he receives research support from Cassava, Cyclerion, Eisai, Lilly, Neurovision, Novo Nordisk, and Vivoryon.
Jennifer Gholson, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Erin Spencer, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AAFP has reviewed Primary Care Perspectives on Alzheimer’s Disease: Adaptive Strategies to Improve Cognitive Assessment, Promote Earlier Diagnosis, and Optimize Care, and deemed it acceptable for AAFP credit. Term of approval is from 02/15/2023 to 06/30/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a CE request form, statements of credit for physicians will be issued within 30 business days.
- 1.00 AAFP ElectiveThe AAFP has reviewed this activity and deemed it acceptable for Live AAFP Elective credits.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation